Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2025-06-24 AGM Information
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
AGM Information Classification · 1% confidence The document explicitly mentions 'Annual General Meeting of Xlife Sciences AG' and details that 'all proposals of the Board of Directors were approved' and provides details on shareholder representation. It also discusses management changes (Dr. Frank Plöger taking a new role) and provides an outlook. This content strongly aligns with materials presented or discussed at an AGM. Although it mentions management changes (MANG) and an outlook (often in ER/IR), the primary context is the formal shareholder meeting where these items were approved/presented. Therefore, AGM-R (AGM Information) is the most appropriate classification.
2025-06-24 English
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
AGM Information Classification · 1% confidence The document explicitly mentions 'Annual General Meeting' ('AGM') in the title and the first paragraph states, 'At today’s Annual General Meeting of Xlife Sciences AG... all proposals of the Board of Directors were approved.' It details the voting results (shares represented) and includes commentary from the Chairman and CEO regarding the past year and future outlook. This content is characteristic of materials presented or summarized following an AGM. Since the document reports on the outcomes and discussions of the meeting itself, the most appropriate classification is AGM Information (AGM-R), rather than a proxy statement (PSI) or voting results announcement (DVA), as it contains broader context and commentary.
2025-06-24 English
Xlife Sciences AG: Erfolgreiche Generalversammlung und Wachstumsaussichten in 2025
AGM Information Classification · 1% confidence The document text explicitly mentions 'Generalversammlung' (General Meeting) and details that the meeting was held today, all motions were approved, and provides quotes from the Chairman and CEO regarding the outcomes and future outlook. The structure and content strongly indicate materials or a summary related to the Annual General Meeting. This aligns perfectly with the AGM Information (AGM-R) definition, which covers presentations and materials shared during the AGM.
2025-06-24 German
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia
Regulatory Filings Classification · 1% confidence The document is a press release dated June 16, 2025, announcing a strategic collaboration (Memorandum of Understanding - MoU) between three companies regarding digital health and precision oncology in Asia. It details the terms of the agreement and includes quotes from the CEOs. It is not a formal regulatory filing like a 10-K, 10-Q (IR), or a specific financial report (AR, FS). It is an announcement of a business development/strategic partnership. Since there is no specific category for 'Business Development Announcement' or 'Press Release,' and the content is a general corporate update that doesn't fit the defined categories (like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS)), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements not covered elsewhere.
2025-06-16 English
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia
Regulatory Filings Classification · 1% confidence The document is a press release dated June 16, 2025, announcing a 'Strategic Collaboration' via a Memorandum of Understanding (MoU) between Xlife Sciences AG and two other companies regarding digital health and precision oncology in Asia. It details the terms of the agreement, includes quotes from CEOs, and provides a financial calendar mentioning future reports (AGM, Half-Year Report). This type of announcement, detailing a significant business development (partnership/alliance) that is not a standard mandatory financial filing (like 10-K, ER, or IR), typically falls under general corporate news or regulatory updates. Since there is no specific category for 'Partnership Announcement' and it is not a formal financial report, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the collaboration involved immediate capital structuring, but the focus here is purely strategic partnership. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for non-standard material events. The document length is substantial (7321 chars), so it is not an RPA.
2025-06-16 English
Strategische Zusammenarbeit zwischen Xlife Sciences AG, Huraypositive Corp. und OncoMASTER Inc. zur Förderung von digitaler Medizin und Präzisionsonkologie in Asien
M&A Activity Classification · 1% confidence The document is a press release dated June 16, 2025, announcing a strategic cooperation (Memorandum of Understanding, MoU) between Xlife Sciences AG and two other companies regarding digital medicine and precision oncology in Asia. It details the terms of the partnership and includes quotes from the CEOs. It is not a formal regulatory filing like a 10-K, nor is it a specific financial report (ER, IR, AR). It is an announcement of a significant business development/partnership. This type of announcement, which details strategic moves but isn't a core financial report or a mandatory regulatory disclosure like insider trading or capital changes, often falls under general Regulatory Filings (RNS) or sometimes a specific category if one fits better. Since it is a general business update/press release announcing a strategic agreement, and there is no specific category for 'Partnership Announcement', RNS (Regulatory Filings / General Regulatory Announcements) is the most appropriate fallback, as it is a formal communication to the market. It is not short enough to be an RPA based on the 'Menu vs Meal' rule, as it contains substantial detail about the agreement itself, not just a link to an attached report.
2025-06-16 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.